RECRUITING

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

Talk to us

Conditions

Liver DiseasesLiver CirrhosisAcute-On-Chronic Liver FailureLiver Transplant; Complications

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.

Official Title

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs

Quick Facts

Study Start:2021-07-08
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04613921

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 1. Male or female subject ≥18 years of age.
  2. 2. Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology).
  3. 3. Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:
  4. * Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list.
  5. * Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD\>20) at the time of listing.
  6. * Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation.
  7. 4. Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Anna Bosch
CONTACT
34 93 227 1400
anna.bosch@efclif.com

Study Locations (Sites)

Cedars-Sinai Comprehensive Transplant Center
Los Angeles, California, 90048
United States
University of Colorado
Aurora, Colorado, 80045
United States
Tampa General Hospital
Tampa, Florida, 33606
United States
Piedmont Healthcare
Atlanta, Georgia, 30309
United States
Northwestern Memorial Hospital
Chicago, Illinois, 60611
United States
The University of Chicago Medicine
Chicago, Illinois, 60637
United States
University of Maryland School of Medicine
Baltimore, Maryland, 21201
United States
Weill Cornell Medicine
New York, New York, 10021
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029-5674
United States
Montefiore Medical Center
New York, New York, 10467
United States
University of Cincinnati
Cincinnati, Ohio, 45219
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Baylor College of Medicine (Scott & White)
Dallas, Texas, 75246
United States
Michael E DeBakey VA Medical Center
Houston, Texas, 77030-4211
United States
Baylor St. Luke's Medical Centre
Houston, Texas, 77030
United States
University of Utah Health
Salt Lake City, Utah, 84132
United States

Collaborators and Investigators

Sponsor: European Foundation for Study of Chronic Liver Failure

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-08
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2021-07-08
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Liver Diseases
  • Liver Cirrhosis
  • Acute-On-Chronic Liver Failure
  • Liver Transplant; Complications